Background
-
to search for yet unknown missense sequence variations within the coding sequence of the human omentin gene,
-
to determine the allelic frequency of newly discovered missense single nucleotide polymorphisms in a cohort of Caucasian patients suffering from T2D and IBD,
-
to describe possible associations of genotype subgroups with standard metabolic parameters and anthropometric data in T2D and disease manifestation in IBD.
Methods
Study populations
Total | Males | Females | p | |
---|---|---|---|---|
n (%) | 276 (100) | 110 (39.9) | 166 (60.1) | |
Age (years ± SEM) | 38.9 ± 0.9 | 38.5 ± 1.5 | 39 ± 1.0 | n.s. |
BMI (kg/m2 ± SEM) | 27.9 ± 0.4 | 27.8 ± 0.6 | 28.1 ± 0.6 | n.s. |
Cholesterol, total (mg/dl ± SEM) | 221 ± 3 | 220 ± 5 | 223 ± 4 | n.s. |
HDL-cholesterol (mg/dl ± SEM) | 58 ± 1 | 50 ± 2 | 62 ± 2 | p < 0.0001 |
LDL-cholesterol (mg/dl ± SEM) | 133 ± 3 | 130 ± 5 | 134 ± 3 | n.s. |
Triglycerides (mg/dl ± SEM) | 168 ± 15 | 199 ± 23 | 151 ± 21 | p = 0.03 |
Uric acid (mg/dl ± SEM) | 5.7 ± 0.1 | 6.8 ± 0.1 | 4.9 ± 0.1 | p < 0.0001 |
Total | Males | Females | p | |
---|---|---|---|---|
n (%) | 114 (100) | 68 (59.6) | 46 (40.4) | |
Age (years ± SEM) | 62.9 ± 0.9 | 60.8 ± 1.3 | 66.2 ± 1.4 | * 0.008 |
BMI (kg/m2 ± SEM) | 28.8 ± 0.7 | 30.3 ± 0.9 | 26.7 ± 0.9 | * 0.016 |
Diabetes duration (years ± SEM) | 7.8 ± 0.8 | 7.6 ± 1.0 | 8.1 ± 1.4 | ns |
HbA
1c
(% ± SEM) | 7.5 ± 0.2 | 7.6 ± 0.2 | 7.4 ± 0.3 | ns |
Cholesterol, total (mg/dl ± SEM) | 199 ± 5 | 196 ± 7 | 203 ± 7 | ns |
HDL-cholesterol (mg/dl ± SEM) | 49 ± 2 | 46 ± 2 | 54 ± 3 | * 0.03 |
LDL-cholesterol (mg/dl ± SEM) | 117 ± 5 | 122 ± 7 | 110 ± 6 | ns |
Triglycerides (mg/dl ± SEM) | 176 ± 11 | 188 ± 14 | 158 ± 15 | ns |
Uric acid (mg/dl ± SEM) | 6.7 ± 0.6 | 7.3 ± 0.9 | 5.9 ± 0.4 | ns |
Therapy | Diabetes | Hypertension | Lipid-lowering |
---|---|---|---|
patients n (%) 114 (100) | patients n (%) 88 (77.2) | patients n (%) 28 (24.6) | |
Medications
| |||
diet | 114 (100) | ||
sulfonylureas | 29 (25.4) | ||
metformin | 44 (38.6) | ||
glitazones | 2 (1.8) | ||
glinides | 7 (6.1) | ||
carboanhydrase inhibitors | 2 (1.8) | ||
insulin (alone/combined) | 52 (45.6) | ||
statins/fibric acid | 28 (24.6) | ||
ACE inhibitors | 40 (35.1) | ||
calcium-channel blockers | 19 (16.7) | ||
diuretic drugs | 41 (36.0) | ||
beta-blockers | 32 (28.1) | ||
others | 3 (2.6) |
Total population | Crohn's Disease | Ulcerative Colitis | |
---|---|---|---|
n (%)
| 190 (100%) | 128 (67.4%) | 62 (32.6%) |
age (years) ± SEM | 37 ± 10 | 36 ± 10 | 39 ± 10 |
female n (%)
| 85 (44.7%) | 64 (50.0%) | 21 (34%) |
male n (%)
| 106 (55.3%) | 64 (50.0%) | 42 (66%) |
Body mass index (BMI) kg/m
2
± SEM | 23.8 ± 3.5 | 23.3 ± 3.6 | 24.7 ± 3.2 |
C-reactive protein mg/dl ± SEM | 14.6 ± 13.5 | 15.1 ± 13.0 | 13.9 ± 14.4 |
systemic steroids n (%)
| 79 (41%) | 46 (36%) | 33 (53%) |
topical steroids n (%)
| 47 (25%) | 24 (18%) | 23 (37%) |
other immuno-suppressants n (%)
| 48 (25%) | 32 (24%) | 16 (25%) |
Vienna classification [22]
n (%):
L1
| - | 21 (16.4%) | - |
L2
| - | 24 (18.8%) | - |
L3
| - | 67 (52.3%) | - |
L4
| - | 16 (12.5%) | - |
B1
| - | 35 (27.3%) | - |
B2
| - | 35 (27.3%) | - |
B3
| - | 58 (45.4%) | - |
Identification of two new single nucleotide polymorphisms
PCR-based RFLP analysis of the omentin Val109Asp SNP
Statistics
Results
Characteristics of the study population
Cohort of non-diabetic controls without a history of IBD
Cohort of patients suffering from T2D
Cohort of patients suffering from UC or CD
Genotyping and allelic frequency of the Asp109Val SNP within exon-4
Cohort of non-diabetic controls without a history of IBD
Cohort of patients suffering from T2D
Val/Val | Val/Asp | Asp/Asp | p | |
---|---|---|---|---|
n (%)
| 12 (10.5) | 44 (38.6) | 58 (50.9) | n.s. |
Age (years) ± SEM | 61.2 ± 3 | 62.7 ± 1.5 | 63.5 ± 1.5 | n.s. |
BMI (kg/m2) ± SEM | 27.9 ± 1.4 | 28.1 ± 0.9 | 29.6 ± 1.1 | n.s. |
HbA1c (% ± SEM) | 7.5 ± 0.4 | 7.4 ± 0.3 | 7.7 ± 0.3 | n.s. |
Cholesterol (mg/dl ± SEM) | 197 ± 14 | 193 ± 9 | 203 ± 7 | n.s. |
HDL-cholesterol (mg/dl ± SEM) | 45 ± 3 | 50 ± 3 | 50 ± 2 | n.s. |
LDL-cholesterol (mg/dl ± SEM) | 122 ± 17 | 121 ± 8 | 111 ± 6 | n.s. |
Triglycerides (mg/dl ± SEM) | 216 ± 40 | 167 ± 18 | 172 ± 12 | n.s. |
Cohort of patients suffering from UC or CD
Total population (n = 190) | Crohn's Disease (n = 131) | Ulcerative Colitis (n = 59) | p | |
---|---|---|---|---|
Genotype
| ||||
Val/Val n (%) | 17 (8.9) | 11 (8.4) | 6 (10.1) | n.s. |
Val/Asp n (%) | 82 (43.2) | 57 (43.5) | 25 (42.4) | n.s. |
Asp/Asp n (%) | 91 (47.9) | 63 (48.1) | 28 (47.5) | n.s. |